Several studies have now reported on the outcomes of combining endocrine therapy (usually fulvestrant) with p53 activation (via standard chemotherapy or MDM2 inhibitors in clinical development) in cell line and xenograft models of endocrine-sensitive and endocrine-resistant ER+ breast cancer (29, 33, 45, 46). Here, MDM2 is linked to breast cancer.